secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001193125-25-314422
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera prices upsized $602M public offering; net ~$656M for pipeline
--------------------------------------------------------------------

- Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.
- Underwriters exercised option to purchase additional 1,050,000 shares in full.
- Net proceeds estimated at ~$656.1M after discounts and expenses.
- Cash runway extended into 2029; funds to advance degrader pipeline and working capital.
- Offering expected to close December 11, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525314422/0001193125-25-314422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525314422/d89982d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-314422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer